The genomic landscape of NSCLC exhibits low frequency deleterious mutations which impair HR, such as copy number alterations or mutations including RAD51 (1.3%), ATM (3%), BRCA2 (1.3%)23 that are enriched in platinum responsive cancers. This evidence concerns the gene ATM and cancer.